Oncopharmpod
Pralsetinib
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:11:47
- Mas informaciones
Informações:
Sinopsis
We have a new drug, pralsetinib, to discuss. It's the 2nd RET inhibitor approved for RET-fusion (+) metastatic NSCLC.
We have a new drug, pralsetinib, to discuss. It's the 2nd RET inhibitor approved for RET-fusion (+) metastatic NSCLC.
